On July 25, 2022 Chimeric Therapeutics Ltd (ASX:CHM) reported that has strengthened its leadership team with the appointment of cell therapy industry leader Dr Jason B. Litten as chief medical officer (CMO) (Press release, Chimeric Therapeutics, JUL 25, 2022, View Source [SID1234616893]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Litten brings almost 15 years of leadership in drug development with the past five years dedicated to advancing NK and CAR T cell therapy clinical-stage programs in oncology.
He will join Chimeric’s s world-class team of cell therapy pioneers and experts focused on the discovery, development and commercialisation of innovative cell therapies.
"Major inflection point"
Chimeric CEO and managing director Jennifer Chow said: "I am truly delighted to welcome Jason to Chimeric as his deep experience and expertise in the development of autologous CAR T and allogeneic NK cell therapies in oncology will be invaluable to us as we continue to advance the development of our CAR T and NK cell therapies.
"Chimeric is moving towards a major inflection point with the expansion of our CHM 0201 and 1101 clinical programs and the initiation of our CHM 2101 clinical program.
"Jason’s unique breadth and depth of cell therapy development experience will provide us with the clinical leadership necessary to advance our development rapidly and effectively.
"Exciting opportunities"
"I am very excited to join Chimeric at this important time in its growth," said Dr Litten.
"The potential for these innovative autologous CAR T cell and allogeneic NK cell therapy programs creates exciting opportunities to bring novel and potentially transformative therapies to cancer patients who need them."
Pioneer in cellular immunotherapy
Entering the cellular immunotherapy field in the early days, Dr Litten has been part of the foundational clinical understanding of cell therapies, working on numerous CAR T and NK cell drug candidates.
Most recently, He served as the CMO at Artiva Biotherapeutics where he led the development of a portfolio of allogeneic Natural Killer (NK) cell therapies.
Prior to Artiva, Dr Litten was vice president of clinical development at Juno Therapeutics where he built and oversaw the autologous solid tumour CAR T and TCRs cell therapy programs.